Cleveland Clinic Lerner Research Institute정재웅 교수
- 교수님 멘토팀
- Department Chair
- Emerging Pathogen Center Director
Dr. Jung’s cancer research focuses on virus-induced cancers, including Kaposi’s sarcoma, the most common tumor in patients with AIDS. For his work in this disease area, the National Cancer Institute awarded him the prestigious Outstanding Investigator Award in 2016.
Dr. Jung also leads theCenter for Global and Emerging Pathogens Research, which is focused on broadening understanding of emerging pathogens.
Dr. Jung has several research projects related to coronaviruses, including vaccine and drug development, and has developed one of the first preclinical models to study SARS-CoV-2 infection and transmission to lead to the development of a COVID-19 vaccine. His vaccine work utilizes nanoparticles that compel the coronavirus to use its own surface protein to produce antibodies that block viral infection. The hope is that this approach will have fewer side effects than other vaccines, especially among the older population that is particularly susceptible to COVID-19.
Dr. Jung and a multi-disciplinary team of scientists and clinicians in Ohio and Florida are collaborating to uncover the mechanisms of infectious agents and virus-induced cancers. He leads virology, immunology and oncology researchers working to make laboratory discoveries about how pathogens spread and cause disease and will collaborate with Cleveland Clinic’sCenter for Therapeutics Discovery. He recently received a $2.8 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine for a newly emerging tick-borne disease.
Cleveland Clinic Lerner Research Institute